The goal of the Small Animal Imaging Lab (SAIL) Core Facility is to provide state-of-the art imaging resources to Moffitt Cancer Center (MCC) members for their basic and translational preclinical studies of rodent cancer models. The SAIL has expanded its services to offer a wide array of multimodality imaging, including MRI, hyperpolarized MRI, CT, PET, SPECT, beta particle, ultrasound, bioluminescence, and fluorescence imaging. These systems allow members to follow tumor development, progression, metastasis and the response to therapy in animal models using quantitative imaging. SAIL provides detection at high spatial resolution of a number of functional, metabolic and anatomical changes, including hypoxia, pH, temporal sensitivity to cellular density, blood flow, and glucose uptake and metabolism. These parameters can be quantified using SAIL's expertise in image feature extraction and analysis to generate an integrated analysis of tumor biology in situ. Animal tumor models are critical for understanding the biology of cancer and the complex responses of distinct tumor types to therapy. Imaging of these animal subjects is a core technology that can precisely define cancer behaviors. Further, as most of these modalities provided by the SAIL are available in the clinic, results with animal tumor models can be readily translated into clinical trials and clinical practice. Multimodality imaging is the key focus of the facility as this provides a broad range of technologies that assist members with their basic and pre-clinical research programs. Over the next funding period, the Specific Aims of the SAIL Core are to:
Aim 1. Assist members in experimental design, interpretation of results, and manuscript and grant preparation.
Aim 2. Provide and expand in vivo and ex vivo imaging and analytical technologies for research involving small animal cancer models.
Aim 3. Provide training and educational opportunities regarding small animal imaging technologies and approaches for members. During the previous award period, SAIL served members from three programs and contributed to 45 publications. In the most recent fiscal year, SAIL served 21 members, with 87% of total usage by peer-review- funded members. The SAIL uses a Laboratory Information Management System (LIMS) to consolidate usage tracking, scheduling, and billing functions. The LIMS also provides a secure repository for project and data management, which is accessible by members and their laboratory staff.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-22
Application #
9868919
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-02-01
Budget End
2021-01-31
Support Year
22
Fiscal Year
2020
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350

Showing the most recent 10 out of 1254 publications